Sohier Hall
President Rocket Science Health
Seminars
Thursday 21st May 2026
Device Technology Should Be Your First Decision, Not Your Last Intranasal drug development programs carry tens of millions in R&D investment and hundreds of millions in sales potential
10:00 am
- Device selection is often a late-stage decision—long after the critical specifications that determine scientific success, commercial viability, and patient experience have been locked in.
- The Rocket Science Health session will give you a front row seat to a live demonstration of novel IN device technology to highlight the importance of early device selection. We will show you how the combination of patented fluidics and human factors-centered design enables precise, repeatable drug deposition to the upper regions of the nasal cavity.
- Walk away from our session knowing why device technology should be considered early in the R&D process and which specifications are most critical to your program’s success.
